Dordaviprone is the first FDA-approved therapy for recurrent H3 K27M-mutant diffuse midline glioma, targeting an ultra-rare brain tumor in children and young adults. The approval was based on a 22% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results